Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)

Next Previous
X
Search
Trial Profile

A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab-deruxtecan (Primary)
  • Indications Adenoid cystic carcinoma; Biliary cancer; Bladder cancer; Carcinoma; Cervical cancer; Endometrial cancer; Gallbladder cancer; Ovarian cancer; Pancreatic cancer; Pelvic cancer; Renal cancer; Salivary gland cancer; Solid tumours; Squamous cell cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms DESTINY-PanTumor02; DPT02
  • Sponsors AstraZeneca; AstraZeneca AB

    • Most Recent Events

    • 02 Dec 2024 According to Daiichi Sankyo Company Media Release, data from DESTINY-PanTumor02 part 2, will be presented in a poster session on December 7, 2024, 5:50 - 6:45 pm at ESMO Asia 2024.
    • 04 Jun 2024 Results (At data cutoff (June 2023), n=24) assessing safety and efficacy of Trastuzumab deruxtecan in patients (pts) with HER2-expressing head and neck tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2024 Results (n=41; At data cutoff June 2023) assessing the efficacy and safety of subgroup analyses in the bladder cohort (urothelial carcinoma including transitional cell carcinoma of the renal pelvis, ureter, urinary bladder, or urethra), and characterize patients with an objective response, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top